Trials / Completed
CompletedNCT03511755
12-Week Study Assessing Change in Psoriasis Severity and Level of Stress Using TEN
A 12-Week, Multicenter, Double-Blind, Controlled, Randomized Study Assessing Change in Psoriasis Severity and Level of Stress in Patients With Moderate to Severe Psoriasis Using Transdermal Electrical Neurosignaling (TEN)
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Thync Global, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a 12-Week, multicenter, double-blind, controlled, randomized study assessing change in psoriasis severity and level of stress in patients with moderate to severe psoriasis treated with TEN. Psoriasis severity and stress levels will be measured at Weeks 0, 4, 8 and 12.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Transdermal Electrical Neuromodulator (TEN) | Thync TEN is a portable, battery-powered, electrical neuromodulation device connected to single-use gel electrode pads that are applied to the base of the neck (C3 to C7). |
Timeline
- Start date
- 2018-03-12
- Primary completion
- 2018-07-24
- Completion
- 2018-07-24
- First posted
- 2018-04-30
- Last updated
- 2018-08-21
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT03511755. Inclusion in this directory is not an endorsement.